Published safety and tolerability findings Published clinical studies on Tirzepatide indicate that the most commonly reported adverse events are gastrointestinal, especially nausea, diarrhoea, decreased appetite, vomiting and constipation
some participants lost more, some less
the others could not be independently verified
2 These body weight reductions exceeded those previously achieved over similar periods of time by adults with T2D treated with other incretinbased therapies, such as dulaglutide, semaglutide, and tirzepatide
Autoimmune patients planning to stop tirzepatide should taper gradually rather than stopping abruptly, and should have their autoimmune specialist monitor disease activity closely during and after the transition
5.11.24 Christine said: Ok for nursing but not pregnancy due to chemical sunscreen